LivingGLP1
Study S002726

Associations of Early Add-On GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy With Mortality and Kidney Outcomes in Adults With Obesity and Type 2 Diabetes Across Cardiovascular-Kidney-Metabolic Stages 2-3: A Target-Trial Emulation

ClinicalTrials.gov recordStudy Protocol and Statistical Analysis Plan (PDF)

Registration

Registration
NCT07465926
Acronym
GLP1-SGLT2-CKM
Study type
OBSERVATIONAL
Status
COMPLETED
Enrollment
451036
Start
2017-01-01
Primary completion
2026-01-31
Lead sponsor
Chung Shan Medical University
Conditions
Cardiovascular-kidney-metabolic Syndrome; Cardiovascular Disease Risk Factor; Kidney Disease; Type 2 Diabetes; Obesity & Overweight
Interventions
DRUG:GLP-1 receptor agonist; DRUG:SGLT2 inhibitor
Results posted
TRUE
Individual participant data sharing
NO
Secondary identifiers
OTHER_GRANT:NSTC 113-2314-B-040-026-MY2; OTHER_GRANT:NSTC 114-2622-B-040-001; OTHER_GRANT:CSH-2025-C-012; OTHER_GRANT:CSH-2025-C-023

Registered primary outcomes

  • All-cause Mortality (Comparison 1) [From index through 36 months]
  • All-cause Mortality (Comparison 2) [From index through 36 months]
  • All-cause Mortality (Comparison 3) [From index through 36 months]
  • All-cause Mortality (Comparison 4) [From index through 36 months]

Linked records (15)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0001693Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era.
Pohlman N, The Journal of clinical endocrinology and metabolism
2025Narrative reviewPMID 40388382DOIregistry reference BACKGROUND:40388382
R0013093SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application.
Bae JH, Diabetes & metabolism journal
2025Narrative reviewPMID 40367988DOIregistry reference BACKGROUND:40367988
R0016105GLP-1-based therapies for diabetes, obesity and beyond.
Drucker DJ, Nature reviews. Drug discovery
2025Narrative reviewPMID 40281304DOIregistry reference BACKGROUND:40281304
R0029579Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits.
Wong CK, The Journal of clinical investigation
2025PreclinicalPMID 41178710DOIregistry reference BACKGROUND:41178710
R0003638Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study.
Huang YN, Diabetes, obesity & metabolism
2024Nonrandomized studyPMID 39171569DOIregistry reference BACKGROUND:39171569
R0003812GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy.
Scheen AJ, Drugs
2024Randomized trialPMID 39342059DOIregistry reference BACKGROUND:39342059
R0006102Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
Simms-Williams N, BMJ (Clinical research ed.)
2024Nonrandomized studyPMID 38663919DOIregistry reference BACKGROUND:38663919
R0011025Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.
Zheng Z, Signal transduction and targeted therapy
2024Other trialPMID 39289339DOIregistry reference BACKGROUND:39289339
R0019647Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic V, The New England journal of medicine
2024Randomized trialPMID 38785209DOIregistry reference BACKGROUND:38785209
R0021954Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials.
Verma S, EClinicalMedicine
2023Randomized trialPMID 36467859DOIregistry reference BACKGROUND:36467859
R0012365Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Kristensen SL, The lancet. Diabetes & endocrinology
2019Systematic reviewPMID 31422062DOIregistry reference BACKGROUND:31422062
R0024139Glucagon-like peptide 1 (GLP-1).
Müller TD, Molecular metabolism
2019PreclinicalPMID 31767182DOIregistry reference BACKGROUND:31767182
R0022060Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, The New England journal of medicine
2016Randomized trialPMID 27295427DOIregistry reference BACKGROUND:27295427
R0022208GLP-1R Agonists and Endothelial Dysfunction: More Than Just Glucose Lowering?
Lovshin J, Diabetes
2015CommentaryPMID 26106189DOIregistry reference BACKGROUND:26106189
R0014123Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells.
Carraro-Lacroix LR, American journal of physiology. Renal physiology
2009PreclinicalPMID 19776173DOIregistry reference BACKGROUND:19776173